Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Where it strikes
Bulk reabsorption + drug uptake (OCT2, OATs)
Fine-tuning of Na, K, Mg, acid & water
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately acute tubular necrosis is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. Mostly expected: naming this lesion on a report can require a biopsy, or the agent has too few reports to divide.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
ATN is systematically undercounted in FAERS — most true cases are filed under the generic “acute kidney injury” term rather than a distinct acute tubular necrosis code, so the literature-only column is expected to run large here.
- NecitumumabAnti-EGFR antibody · FAERS only26.96 (11.16–65.12) · n=5 Reporting signal, fragile (few reports).
- PemetrexedAntifolate14.78 (13.15–16.61) · n=294 Reporting signal.
- ZongertinibHER2 TKI · FAERS only11.40 (1.60–81.41) · n=1 Reporting signal, fragile (few reports).
- Zoledronic acidBisphosphonate8.44 (7.40–9.64) · n=228 Reporting signal.
- SirolimusmTOR inhibitor8.39 (6.50–10.82) · n=60 Reporting signal.
- PembrolizumabPD-1 checkpoint inhibitor · FAERS only8.08 (7.25–9.00) · n=350 Reporting signal.
- DostarlimabAnti-PD-1 antibody · FAERS only7.70 (3.85–15.42) · n=8 Reporting signal, fragile (few reports).
- ClofarabinePurine analog5.81 (2.77–12.21) · n=7 Reporting signal, fragile (few reports).
- AmivantamabEGFR-MET bispecific antibody · FAERS only5.31 (2.85–9.88) · n=10 Reporting signal.
- Tisotumab vedotinAntibody-drug conjugate (tissue factor/MMAE) · FAERS only4.95 (1.24–19.83) · n=2 Reporting signal, fragile (few reports).
- VinblastineVinca alkaloid · FAERS only4.84 (2.01–11.64) · n=5 Reporting signal, fragile (few reports).
- CisplatinPlatinum agent4.66 (4.04–5.38) · n=191 Reporting signal.
- CarboplatinPlatinum agent4.37 (3.88–4.91) · n=292 Reporting signal.
- EverolimusmTOR inhibitor · FAERS only4.08 (3.37–4.95) · n=106 Reporting signal.
- BleomycinAntitumor antibiotic · FAERS only3.66 (2.36–5.68) · n=20 Reporting signal.
- BendamustineAlkylator · FAERS only3.48 (2.58–4.67) · n=44 Reporting signal.
- TrabectedinMarine alkylating agent3.23 (1.21–8.61) · n=4 Reporting signal, fragile (few reports).
- CobimetinibMEK inhibitor2.56 (1.15–5.71) · n=6 Reporting signal, fragile (few reports).
- BinimetinibMEK inhibitor2.38 (1.28–4.43) · n=10 Reporting signal.
- IfosfamideOxazaphosphorine alkylator2.30 (1.56–3.38) · n=26 Reporting signal.
- ImatinibBCR-ABL TKI1.78 (1.28–2.49) · n=35 Reporting signal.
- OxaliplatinPlatinum agent1.63 (1.27–2.07) · n=65 Reporting signal.
- NivolumabPD-1 checkpoint inhibitor1.44 (1.15–1.81) · n=75 Reporting signal.
- RituximabAnti-CD20 antibody1.29 (1.10–1.52) · n=149 Reporting signal.
- PentostatinPurine analog (ADA inhibitor)4.33 (0.61–30.79) · n=1 No reporting signal.
- RaltitrexedAntifolate (TS inhibitor)3.57 (0.50–25.41) · n=1 No reporting signal.
- Idecabtagene vicleucelBCMA CAR-T cell therapy3.05 (0.76–12.23) · n=2 No reporting signal.
- NedaplatinPlatinum agent2.18 (0.31–15.51) · n=1 No reporting signal.
- EncorafenibBRAF inhibitor1.67 (0.87–3.22) · n=9 No reporting signal.
- VemurafenibBRAF inhibitor1.42 (0.74–2.73) · n=9 No reporting signal.
- CarfilzomibProteasome inhibitor1.40 (0.91–2.15) · n=21 No reporting signal.
- AzacitidineHypomethylating agent1.07 (0.66–1.72) · n=17 No reporting signal.
- Methotrexate (high-dose)Antifolate1.03 (0.91–1.16) · n=268 No reporting signal.
- ElranatamabBispecific (BCMA×CD3)1.00 (0.14–7.13) · n=1 No reporting signal.
- Enfortumab vedotinAntibody-drug conjugate (Nectin-4/MMAE)0.96 (0.36–2.57) · n=4 No reporting signal.
- Arsenic trioxideDifferentiating agent0.94 (0.23–3.75) · n=2 No reporting signal.
- Ciltacabtagene autoleucelBCMA CAR-T cell therapy0.86 (0.28–2.68) · n=3 No reporting signal.
- Tretinoin (ATRA)Retinoid (differentiating agent)0.63 (0.20–1.97) · n=3 No reporting signal.
- PegaspargaseEnzyme (asparaginase)0.61 (0.23–1.63) · n=4 No reporting signal.
- IbrutinibBTK inhibitor0.51 (0.34–0.78) · n=22 No reporting signal.
- DabrafenibBRAF inhibitor0.45 (0.19–1.07) · n=5 No reporting signal.
- LenalidomideImmunomodulatory drug (IMiD)0.39 (0.32–0.48) · n=90 No reporting signal.
- Trastuzumab deruxtecanAntibody-drug conjugate (HER2/DXd)0.35 (0.09–1.39) · n=2 No reporting signal.
- ProcarbazineHydrazine alkylating agent0.33 (0.05–2.33) · n=1 No reporting signal.
- ErlotinibEGFR TKI0.31 (0.10–0.97) · n=3 No reporting signal.
- VenetoclaxBCL-2 inhibitor0.30 (0.16–0.56) · n=10 No reporting signal.
- IbandronateBisphosphonate0.16 (0.02–1.15) · n=1 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no ATN reports, or too few (count in brackets): Afatinib, Alpelisib, Avutometinib, Blinatumomab, Datopotamab deruxtecan (Dato-DXd), Enasidenib, Fotemustine, Ivosidenib, Lifileucel, Lisocabtagene maraleucel, Lurbinectedin, Melphalan flufenamide (melflufen), Mobocertinib, Nimustine (ACNU), Obinutuzumab, Pacritinib, Penpulimab, Pralatrexate, Sacituzumab govitecan, Sonidegib, Sotorasib, Streptozocin, Tagraxofusp, Talquetamab, Tarlatamab, Teclistamab, Telisotuzumab vedotin (Teliso-V)
No ratio — under 50 FAERS reports in total: Gallium nitrate, Odronextamab, Pivekimab sunirine, Plicamycin (mithramycin), Sugemalimab, Tasonermin
No FAERS reports under the agent's name: Iobenguane I-131, Samarium-153 lexidronam
All 72 agents documented with ATN in the atlas are shown whether or not FAERS flags them, plus the 27 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (BRAF / MEK inhibitors (vemurafenib · dabrafenib · trametinib); CAR-T cell therapy; mTOR inhibitors (everolimus · temsirolimus)) are not asked of FAERS; their member agents are ranked individually. 41 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →Prevention is the mainstay; once established, supportive care while the tubule recovers.
Drug-level levers
- Hold the agent for a significant creatinine rise; resume only after recovery.
- Dose-reduce or extend the dosing interval for lower-grade or recurrent injury.
- Switch within class to a less nephrotoxic platinum (carboplatin or nedaplatin) when a platinum must continue.
- Switch out of class to a non-nephrotoxic regimen if re-exposure risk is unacceptable.
Pharmacologic toolkit
- Volume expansion — Isotonic saline before and after dosing is the best-evidenced preventive measure for cisplatin ATN.
- Magnesium repletion — Replace urinary magnesium and potassium losses; magnesium supplementation may be renoprotective.
- Avoid co-nephrotoxins — Hold NSAIDs, aminoglycosides, and iodinated contrast where possible.
When to biopsy
Rarely needed — the diagnosis is usually clinical (timing, muddy-brown granular casts). Reserve biopsy for atypical features or when an alternative lesion (AIN, TMA) is suspected.
Monitoring
- · Creatinine / eGFR before each cycle
- · Serum magnesium and potassium
- · Urine output and sediment
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to acute tubular necrosis.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Offending agents
Signature offenders
26Agents for which acute tubular necrosis is the defining renal lesion.